Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2000

View Archived Issues

Orion highlights R&D developments for 1999

Immunomedics successfully delivers cancer drug through bispecific fusion proteins

ML Laboratories makes offers to acquire Cobra Therapeutics

VaxGen highlights significant events in Q4 1999

Taro begins phase I testing of proprietary anticonvulsant

Cinnamamide: a lead compound for the design of structurally unique MMP inhibitors

SciClone's Zadaxin boosts immune recognition of tumor cells

UroGenesys and Protein Pathways form alliance

HemispheRx Biopharma seeks patents for HIV gene therapy

Calcium antagonists and glutamate release inhibitors in development at Eisai

New antitumor compounds from Shionogi act on ras-mediated cell signaling

Wealth of preclinical, clinical data on desloratadine presented at AAAAI meeting

Warner-Lambert patents reduced dipeptide N-type Ca2+ channel blockers

U.S. university researchers synthesize new series of PPARgamma agonists

Piperazine derivatives synthesized at Samjin exert potent antitumor activity with low toxicity

New 5alpha-reductase inhibitors in the pipeline at Kotobuki

AAAAI presentations on efficacy of E25 in asthma and seasonal allergic rhinitis

NIAID researchers describe antiscrapie compounds with promising activity in preclinical models

Lead structure for the design of tissue-selective ER ligands discovered at Novo Nordisk

AC-326-alpha, a new phosphoglycolipid antibiotic of the moenomycin group

DuPont and Aventis form discovery and development alliance

FDA approves ReFacto for hemophilia A

Effects of NO-1886 on lipid levels and LPL activity in WHHL rabbits

MetaPhore targets pain as the first indication for lead SOD mimetic

Positive developments reported at AAAAI meeting for IL-9 antibody with potential in asthma

Patent broadens protection for Endorex's oral/mucosal drug delivery system

NeoTherapeutics' nerve regeneration platform receives further patent protection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...